2027 Competition Sales 
Contrarian Sales Techniques
FEBRUARY 1, 2023
After reading the "sales strategy for milk products" article , I learned some valuable insights that I believe can be applied to any industry, not just the milk product industry. Understanding these groups will allow you to create targeted marketing campaigns and tailor your sales pitch to meet their needs.
PM360
SEPTEMBER 21, 2023
They do not have biosimilar or generic competition available in the market. Over the next few weeks, manufacturers will submit a range of clinical, marketing, sales, pricing, and patient data, and then meet with CMS to discuss submissions later this fall. They do not qualify for any exemption (e.g.,
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
pharmaphorum
SEPTEMBER 21, 2022
Novartis is running out of options in its bid to defend oral muscular sclerosis therapy Gilenya from early generic competition in the US. After initially upholding the patent in January, the CAFC subsequently ruled in June that it was not valid, opening the door to low-cost competition to Novartis’ third biggest-selling product.
pharmaphorum
JULY 26, 2022
The looming competition piles further pressure on Biogen, whose MS franchise is already beset by generic competition to oral therapy Tecfidera (dimethyl glutamate), while its attempt to build a market for Alzheimer’s therapy Aduhelm (aducanumab) has ended in failure.
European Pharmaceutical Review
JANUARY 10, 2023
Treatments identified in the report are predicted to be potential blockbuster drugs by 2027 or have potential to serve unmet patient needs for millions of patients worldwide. It offers a less-frequent dosing schedule and good safety profile, which is likely to be attractive to clinicians and patients. .
pharmaphorum
OCTOBER 17, 2022
Novartis’ hopes that the Supreme Court would protect its big-selling multiple sclerosis drug Gilenya from generic competition have been dashed. 9,187,405, granted in 2015, which comes to an end in 2027. If they do so, Novartis has predicted it will lose $300 million in sales over the remainder of this year.
pharmaphorum
JULY 18, 2022
Tysabri made worldwide sales of just under $2.1 It had expected the drug would not face biosimilar competition in Europe until at least 2027. billion last year, split roughly half and half between the US and the rest of the world, and is Biogen’s biggest seller. Europe accounted for an estimated $850 million of the total.
Expert insights. Personalized for you.
52 
Let's personalize your content